- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.04. | Ikena Oncology, Inc.: Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum | 1 | GlobeNewswire (USA) | ||
| 19.03. | The Analyst Landscape: 4 Takes On Ikena Oncology | 2 | Benzinga.com | ||
| 12.03. | Ikena Oncology: Q4 Earnings Insights | 1 | Benzinga.com | ||
| 12.03. | Ikena Oncology, Inc.: Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results | 139 | GlobeNewswire (Europe) | IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including additional data from EHE patients in... ► Artikel lesen | |
| 12.03. | Ikena Oncology, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 12.03. | Ikena Oncology, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 21.02. | Ikena Oncology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.02. | Ikena Oncology, Inc.: Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer | 170 | GlobeNewswire (Europe) | Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise Dr. Germa will drive clinical development strategy... ► Artikel lesen | |
| 19.01. | Ikena Oncology Refocuses on Key Programs: Analysts Maintain Outperform Ratings Amid Strategic Organizational Changes | 2 | Benzinga.com | ||
| 19.01. | Biotech layoffs strike hard with PMV Pharma, Ikena, and Bayer sacking staff | 25 | Pharmaceutical Technology | ||
| 19.01. | Ikena fires 35% of staff to funnel funds into clinical oncology programmes | 1 | Pharmaceutical Technology | ||
| 19.01. | Jilted by Bristol Myers, Ikena cuts headcount by 35% in retreat from drug discovery | 26 | FierceBiotech | ||
| 18.01. | Ikena to cut 35% of workforce, extend cash runway into 2H 2026 | 2 | Seeking Alpha | ||
| 18.01. | Ikena Oncology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.01. | Ikena Oncology, Inc.: Ikena Oncology Outlines Key Priorities and Provides Corporate Updates | 283 | GlobeNewswire (Europe) | IK-930 optimized formulation now in the clinic; on track to deliver additional monotherapy data in 2H 2024 IK-595 first cohort treated and cleared safety evaluation window Focused execution on core... ► Artikel lesen | |
| 14.11.23 | DelveInsight Business Research, LLP: Neurofibromatosis Type 2 Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - Novartis, AstraZeneca, GlaxoSmithKline, Ikena, SpringWorks, Vivace, Recursion | 766 | PR Newswire | The increase in the neurofibromatosis type 2 market size is a direct consequence of the increasing number of surgical procedures, the rise in the patient population of neurofibromatosis type... ► Artikel lesen | |
| 09.11.23 | Why Is Cancer Firm Ikena Oncology Stock Trading Lower Today? | 1 | Benzinga.com | ||
| 09.11.23 | Ikena tumbles after early data for lead asset, Q3 financials | 4 | Seeking Alpha | ||
| 09.11.23 | Ikena Oncology down on missing Q3 revenue estimates | 3 | Reuters | ||
| 09.11.23 | Atara Biotherapeutics, Ikena Oncology among healthcare movers | 23 | Seeking Alpha |
Seite:
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MORPHOSYS | 67,70 | 0,00 % | Deutsche Telekom, Evotec, Morphosys, Mutares, Nel ASA - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| EPIGENOMICS | 1,595 | -2,45 % | EQS-NVR: Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Epigenomics AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG... ► Artikel lesen | |
| BIOGEN | 179,00 | +0,03 % | Biogen Unusual Options Activity For April 18 | ||
| CORE ONE LABS | 0,150 | +4,18 % | Sondermeldung: Gar mehrere hundert Prozent bis zur Bescherung? Wo die Community jetzt auf eine Jahresendrallye spekuliert… | ||
| DEFENCE THERAPEUTICS | 0,986 | +4,45 % | KI im Gesundheitswesen mit evotec, Defence Therapeutics, Bayer: Revolutionäre Fortschritte und medizinische Durchbrüche | Im Gesundheitswesen nimmt Künstliche Intelligenz (KI) immer mehr an Fahrt auf. KI-basierte Systeme können medizinische Datenbanken nutzen, um in der Forschung kostbare Zeit zu sparen, die es Unternehmen... ► Artikel lesen | |
| VIKING THERAPEUTICS | 61,06 | +0,43 % | Market Whales and Their Recent Bets on VKTX Options | ||
| GINKGO BIOWORKS | 0,925 | 0,00 % | Il Granaio delle Idee and Ginkgo Bioworks Announce Strategic Collaboration to Optimize Sourdough Strains for Bakery Products | IGDI will leverage Ginkgo's Adaptive Laboratory Evolution technology to improve its sourdough starter culture product PADUA, Italy and BOSTON, April 16, 2024 /PRNewswire/ -- Il Granaio delle Idee... ► Artikel lesen | |
| BEAM THERAPEUTICS | 24,310 | 0,00 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,975 | 0,00 % | Oncolytics Biotech Inc.: Oncolytics Biotech Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA | Requested for Q2 2024, the Type C meeting is to focus on planned registration-enabling trial in HR+/HER2- metastatic breast cancer
Overall survival results from the randomized HR+/HER2- metastatic... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,400 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer | Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion's Board of DirectorsSALT LAKE... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 26,310 | 0,00 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| ASSERTIO | 0,754 | -3,33 % | Assertio Holdings, Inc.: Assertio Reports Fourth Quarter and Full Year 2023 Financial Results | Fourth Quarter Net Product Sales $32.5 Million, Cash Flow from Operations of $5.7 Million 2024 Full Year Outlook for Net Product Sales of $110 to $125 Million, Adjusted EBITDA of... ► Artikel lesen | |
| G1 THERAPEUTICS | 3,776 | -3,43 % | G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024 | ||
| SIGA TECHNOLOGIES | 8,240 | 0,00 % | SIGA Technologies - Positive signals abound | SIGA Technologies announced a strategic step in fortifying its distribution partner, Meridian, allowing greater control over planning and executing its international development efforts, a key growth... ► Artikel lesen | |
| MERRIMACK PHARMACEUTICALS | 14,680 | 0,00 % | Merrimack Pharmaceuticals, Inc. Reports Full Year 2023 Financial Results | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced its full year 2023 financial results for the period ended December... ► Artikel lesen |
IKENA ONCOLOGY INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,280 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
